BIIB:NASDAQ
Biogen Inc
$233.48
arrow_upward
+0.36%(+0.83) 1D
$236.00
arrow_upward
+1.08% (+2.52)bedtimeAfter hours
Closed: Oct 19, 4:00:00 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB...
Open
$231.81
High
$236.00
Low
$231.04
Mkt. cap
34.50B
Avg. vol.
1.14M
Volume
949.72K
P/E ratio
41.35
52-wk high
$240.99
52-wk low
$138.00
EPS
$5.65
Beta
0.09
Shares outstanding
147.75M
No. of employees
8K
Open
$231.81
High
$236.00
Low
$231.04
Mkt. cap
34.50B
Avg. vol.
1.14M
Volume
949.72K
P/E ratio
41.35
52-wk high
$240.99
52-wk low
$138.00
EPS
$5.65
Beta
0.09
Shares outstanding
147.75M
No. of employees
8K
News stories
From web sources and news partners
Zacks
·
11 hours ago
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
Investing.com Canada
·
12 hours ago
Biogen to present 76-week Empaveli data at kidney conference By Investing.com
TipRanks
·
2 days ago
OCUL, IDXX, BIIB, BFLY, TMUS Trending With Analysts
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com
Analyst ratings
Based on 24 analysts giving stock ratings to BIIB in the past 3 months
Buy
Buy
17
Hold
6
Sell
1
12-month forecast
Based on 24 Wall Street analysts offering 12 month price targets for BIIB in the last 3 months.
Highest
Current $233.48
$300.00 (+28.49%)
Average
$241.96 (+3.63%)
Lowest
$175.00 (-25.05%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Mohit Bansal Wells Fargo | Buy | Maintained | $250.00 | +7.1% | 10/15/2026 |
Evan Seigerman BMO Capital | Hold | Maintained | $220.00 | -5.8% | 10/12/2026 |
Geoff Meacham Citi | Hold | Maintained | $215.00 | -7.9% | 10/12/2026 |
David Amsellem Piper Sandler | Buy | Reiterated | $245.00 | +4.9% | 10/12/2026 |
Chris Schott J.P. Morgan | Buy | Upgraded | $300.00 | +28.5% | 10/12/2026 |
Michael Yee UBS | Buy | Reiterated | $270.00 | +15.6% | 10/09/2026 |
Brian Abrahams RBC Capital | Buy | Maintained | $256.00 | +9.6% | 10/08/2026 |
Ami Fadia Needham | Buy | Maintained | $256.00 | +9.6% | 10/06/2026 |
Andrew Tsai Jefferies | Buy | Maintained | $255.00 | +9.2% | 10/05/2026 |
Eve Burstein Bernstein | Buy | Maintained | $236.00 | +1.1% | 09/25/2026 |
Morten Herholdt HSBC | Sell | Maintained | $175.00 | -25% | 09/10/2026 |
Alexandria Hammond Wolfe Research | Buy | Upgraded | $300.00 | +28.5% | 08/13/2026 |
Emily Field Barclays | Hold | Maintained | $200.00 | -14.3% | 08/12/2026 |
Salim Syed Mizuho Securities | Buy | Maintained | $241.00 | +3.2% | 08/03/2026 |
Paul Matteis Stifel Nicolaus | Buy | Maintained | $242.00 | +3.6% | 08/02/2026 |
Andrew Fein H.C. Wainwright | Buy | Reiterated | $251.00 | +7.5% | 07/30/2026 |
Danielle Brill Truist Financial | Buy | Reiterated | $235.00 | +0.7% | 07/31/2026 |
Sumant Kulkarni Canaccord Genuity | Buy | Reiterated | $248.00 | +6.2% | 07/30/2026 |
Phil Nadeau TD Cowen | Buy | Reiterated | $225.00 | -3.6% | 07/30/2026 |
Terence Flynn Morgan Stanley | Hold | Maintained | $231.00 | -1.1% | 07/30/2026 |
Myles Minter William Blair | Buy | Maintained | - | - | 07/29/2026 |
Laura Chico Wedbush | Hold | Maintained | $215.00 | -7.9% | 07/31/2026 |
Jason Zemansky Bank of America Securities | Hold | Reiterated | $219.00 | -6.2% | 07/29/2026 |
Jay Olson Oppenheimer | Buy | Maintained | $300.00 | +28.5% | 07/23/2026 |
Yatin Suneja Guggenheim | Buy | Reiterated | $280.00 | +19.9% | 07/21/2026 |
Salveen Richter Goldman Sachs | Buy | Maintained | $250.00 | +7.1% | 07/13/2026 |
Thomas Shrader BTIG | Hold | Maintained | - | - | 07/13/2026 |
Jasper Hellweg Argus Research | Hold | Maintained | - | - | 07/10/2026 |
Ananda Ghosh H.C. Wainwright | Buy | Maintained | $237.00 | +1.5% | 07/01/2026 |
Eric Schmidt FCA Cantor Fitzgerald | Buy | Initiated | $206.00 | -11.8% | 06/22/2026 |
Umer Raffat Evercore ISI | Buy | Initiated | - | - | 05/15/2026 |
Ilya Zubkov Freedom Capital Markets | Buy | Upgraded | $245.00 | +4.9% | 05/01/2026 |
William Pickering Bernstein | Hold | Maintained | $201.00 | -13.9% | 02/06/2026 |
Next call in 9 days
Wed, Oct 28, 2:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $2.00
Revenue / Est. (USD)
- / 2.63B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 2.53B | 2.28B | 2.48B | 2.74B |
Cost of goods sold | 508.60M | 443.40M | 610.20M | 611.60M |
Cost of revenue | 508.60M | 443.40M | 610.20M | 611.60M |
Research and development expenses | 431.80M | 477.10M | 482.20M | 492.10M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 592.80M | 685.20M | 607.30M | 709.70M |
Operating expense | 1.25B | 1.36B | 1.30B | 1.44B |
Total operating expenses | 1.76B | 1.81B | 1.91B | 2.05B |
Operating income | 778.60M | 471.60M | 567.40M | 685.60M |
Other non operating income | 15.80M | 17.40M | -1.10M | 3.00M |
EBT including unusual items | 557.30M | -56.00M | 377.70M | 132.40M |
EBT excluding unusual items | 748.30M | 447.00M | 530.10M | 625.10M |
Income tax expense | 90.80M | -7.10M | 58.20M | 34.90M |
Effective tax rate | 16.29% | 12.68% | 15.41% | 26.36% |
Other operating expenses | 87.20M | 69.90M | 74.20M | 68.80M |
Net income | 466.50M | -48.90M | 319.50M | 97.50M |
Net profit margin | 18.40% | -2.15% | 12.89% | 3.56% |
Earnings per share | 4.81 | 1.99 | 3.57 | 3.60 |
Interest and investment income | 31.60M | 37.20M | 37.90M | 25.30M |
Interest expense | -67.40M | -67.50M | -67.60M | -82.30M |
Net interest expenses | -35.80M | -30.30M | -29.70M | -57.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 980.80M | 671.80M | 771.80M | 921.70M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1